Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

Q: What does CUSIP 761330109 represent in this 13F holders report?

CUSIP 761330109 is the security identifier for RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q3 2022?

178 institutional investors reported RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q3 2022. Use the holders table for investor-level position and value details.

CUSIP: 761330109

Q3 2022 13F Holders as of 30 Sep 2022

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 104,661,494
Total 13F shares: 67,635,567
Share change: +11,589,560
Total reported value: $1,824,203,436
Put/Call ratio: 39%
Price per share: $27.00
Number of holders: 178
Value change: +$329,402,349
Number of buys: 111
Number of sells: 58

Quarterly Holders Quick Answers

What is CUSIP 761330109?
CUSIP 761330109 identifies RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2022
Previous quarter: Q2 2022

Recent filing periods for CUSIP 761330109:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
JPMORGAN CHASE & CO	13F	Company	6.4%	6,687,925	$92,427,000	—	30 Jun 2022	13F
BlackRock Finance, Inc.	13F	Company	5.4%	5,684,831	$78,564,000	—	30 Jun 2022	13F
Capital World Investors	13F	Company	4.4%	4,590,000	$63,434,000	—	30 Jun 2022	13F
Palo Alto Investors LP	13F	Company	4.2%	4,405,039	$60,878,000	—	30 Jun 2022	13F
VANGUARD GROUP INC	13F	Company	3.5%	3,703,055	$51,176,000	—	30 Jun 2022	13F
Polar Capital Holdings Plc	13F	Company	3%	3,117,052	$43,078,000	—	30 Jun 2022	13F
FRANKLIN RESOURCES INC	13F	Company	2.3%	2,366,367	$32,703,000	—	30 Jun 2022	13F
STATE STREET CORP	13F	Company	1.7%	1,779,793	$24,597,000	—	30 Jun 2022	13F
JENNISON ASSOCIATES LLC	13F	Company	1.7%	1,755,703	$24,264,000	—	30 Jun 2022	13F
BAMCO INC /NY/	13F	Company	1.6%	1,683,008	$23,259,000	—	30 Jun 2022	13F
HealthCor Management, L.P.	13F	Company	1.4%	1,418,088	$19,598,000	—	30 Jun 2022	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.2%	1,236,952	$17,094,000	—	30 Jun 2022	13F
HighTower Advisors, LLC	13F	Company	1.2%	1,224,162	$16,917,000	—	30 Jun 2022	13F
FMR LLC	13F	Company	1.2%	1,214,313	$16,782,000	—	30 Jun 2022	13F
RICE HALL JAMES & ASSOCIATES, LLC	13F	Company	1%	1,085,340	$14,999,000	—	30 Jun 2022	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.79%	828,925	$11,456,000	—	30 Jun 2022	13F
D. E. Shaw & Co., Inc.	13F	Company	0.78%	817,740	$11,302,000	—	30 Jun 2022	13F
CITADEL ADVISORS LLC	13F	Company	0.74%	769,584	$10,635,000	—	30 Jun 2022	13F
NORTHERN TRUST CORP	13F	Company	0.65%	678,300	$9,373,000	—	30 Jun 2022	13F
Point72 Asset Management, L.P.	13F	Company	0.58%	605,574	$8,369,000	—	30 Jun 2022	13F
PERCEPTIVE ADVISORS LLC	13F	Company	0.55%	572,514	$7,912,000	—	30 Jun 2022	13F
MORGAN STANLEY	13F	Company	0.48%	503,061	$6,953,000	—	30 Jun 2022	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.46%	481,715	$6,658,000	—	30 Jun 2022	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.45%	470,124	$6,497,000	—	30 Jun 2022	13F
Walleye Capital LLC	13F	Company	0.44%	464,970	$6,426,000	—	30 Jun 2022	13F
Essex Woodlands Management, Inc.	13F	Company	0.44%	457,085	$6,317,000	—	30 Jun 2022	13F
Rhenman & Partners Asset Management AB	13F	Company	0.43%	450,000	$6,219,000	—	30 Jun 2022	13F
Nuveen Asset Management, LLC	13F	Company	0.34%	359,120	$4,963,000	—	30 Jun 2022	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.33%	344,688	$4,764,000	—	30 Jun 2022	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.33%	344,467	$4,760,000	—	30 Jun 2022	13F
Aubrey Rankin	3/4/5	Director	— class O/S missing	570,004	$4,257,930	—	15 Mar 2022	3/4/5
VOLORIDGE INVESTMENT MANAGEMENT, LLC	13F	Company	0.29%	303,076	$4,189,000	—	30 Jun 2022	13F
Bank of New York Mellon Corp	13F	Company	0.25%	258,964	$3,579,000	—	30 Jun 2022	13F
Cubist Systematic Strategies, LLC	13F	Company	0.23%	245,212	$3,389,000	—	30 Jun 2022	13F
Granahan Investment Management, LLC	13F	Company	0.21%	223,631	$3,091,000	—	30 Jun 2022	13F
ROTHSCHILD & CO ASSET MANAGEMENT US INC.	13F	Company	0.21%	216,470	$2,992,000	—	30 Jun 2022	13F
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	13F	Company	0.17%	175,179	$2,421,000	—	30 Jun 2022	13F
BROOKFIELD Corp /ON/	13F	Company	0.15%	161,748	$2,235,000	—	30 Jun 2022	13F
Swiss National Bank	13F	Company	0.15%	161,250	$2,228,000	—	30 Jun 2022	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.14%	143,265	$1,980,000	—	30 Jun 2022	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.13%	135,044	$1,866,000	—	30 Jun 2022	13F
Evolutionary Tree Capital Management, LLC	13F	Company	0.13%	134,188	$1,854,000	—	30 Jun 2022	13F
Assenagon Asset Management S.A.	13F	Company	0.12%	130,648	$1,806,000	—	30 Jun 2022	13F
CASTLEARK MANAGEMENT LLC	13F	Company	0.12%	129,313	$1,787,000	—	30 Jun 2022	13F
FEDERATED HERMES, INC.	13F	Company	0.12%	121,400	$1,677,000	—	30 Jun 2022	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	0.11%	116,447	$1,609,000	—	30 Jun 2022	13F
PDT Partners, LLC	13F	Company	0.11%	110,690	$1,530,000	—	30 Jun 2022	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.1%	108,400	$1,498,000	—	30 Jun 2022	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.1%	104,912	$1,449,000	—	30 Jun 2022	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.09%	92,337	$1,277,000	—	30 Jun 2022	13F

Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q3 2022

As of 30 Sep 2022, Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by 178 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 67,635,567 shares. The largest 10 holders included Capital World Investors, BlackRock Inc., JPMORGAN CHASE & CO, Polar Capital Holdings Plc, Palo Alto Investors LP, VANGUARD GROUP INC, FRANKLIN RESOURCES INC, FMR LLC, BAMCO INC /NY/, and STATE STREET CORP. This page lists 178 institutional shareholders reporting positions in this security for the Q3 2022 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2022 vs Q2 2022 Across Filers

Q2 2022 holders

156

Q3 2022 holders

178

Holder diff

Investor	Q2 2022 Shares	Q3 2022 Shares	Share Diff	Share Chg %	Q2 2022 Value $	Q3 2022 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.